Results 41 to 50 of about 6,598 (226)

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome

Microbiology Spectrum, 2023
People with cystic fibrosis (pwCF) experience a range of persistent gastrointestinal symptoms throughout life. There is evidence indicating interaction between the microbiota and gut pathophysiology in CF.
Ryan Marsh, Claudio Dos Santos, Liam Hanson, Christabella Ng, Giles Major, Alan R. Smyth, Damian Rivett, Christopher van der Gast   +7 more
doaj   +1 more source

Personalized Medicine; a Potential Therapy for Cystic Fibrosis [PDF]

, 2023
Cystic Fibrosis (CF) is an inherited disorder caused by mutations in CFTR gene that codes for Cystic Fibrosis Transmembrane-conductance Receptor anion channel.
Ashraf, Aqsa, Ghani, Muhammad Usman, Hassan, Mahmood ul, Khan, Muhammad Umer, Mehdi, Zohair, Rehman, Hafiz Muzzammel   +5 more
core   +2 more sources

A rapid RP-HPLC method for the simultaneous estimation of Ivacaftor and Tezacaftor and in silico study of their metabolitic products

Future Journal of Pharmaceutical Sciences, 2021
Background This study was designed to develop a reliable method for estimation of Ivacaftor and Tezacaftor in pure and its pharmaceutical dosage form by RP-HPLC in human plasma.
Madhuri Donakonda, Srija Indrakanti, Praveen Kumar Pasala, Malleswari Desari, Shireesha Kammari   +4 more
doaj   +1 more source

Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series

Frontiers in Pharmacology, 2023
The prevalence of mental health disorders is high among people with Cystic Fibrosis. The psychological symptoms in CF are associated with poor adherence, worse treatment outcomes, and greater health utilization/cost.
Hisham Ibrahim, Hisham Ibrahim, Hammad Danish, David Morrissey, David Morrissey, Kevin F. Deasy, Kevin F. Deasy, Mairead McCarthy, James Dorgan, Claire Fleming, Ciara Howlett, Sarah Twohig, Tamara Vagg, Tamara Vagg, Desmond M. Murphy, Desmond M. Murphy, Michael Maher, Michael Maher, Barry J. Plant, Barry J. Plant   +19 more
doaj   +1 more source

Lingering Identity as Chronically Ill and the Unanticipated Effects of Life-Changing Precision Medicine in Cystic Fibrosis: A Case Report

Journal of Patient Experience, 2021
Cystic fibrosis (CF) is the leading genetic disease among Caucasians; however, advances in diagnosis and treatment have improved both quality and quantity of life for those affected.
Sigrid Ladores PhD, RN, PNP, CNE, FAAN, Morgan Polen   +1 more
doaj   +1 more source

Current prices versus minimum costs of production for CFTR modulators [PDF]

, 2022
BACKGROUND: While the clinical benefits of CFTR modulators are clear, their high prices render them inaccessible outside of the world's richest countries.
Fortunak, J, Guo, J, Hill, A, Wang, J, Zhang, J   +4 more
core   +1 more source

Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving Elexacaftor-Tezacaftor-Ivacaftor [case report]. [PDF]

, 2022
Before the arrival of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators women with CF and impaired lung function were experiencing a high risk of complications and mortality during and the years after pregnancy.
Balmpouzis, Zisis, Baud, David, Faure van Rossum, Annabelle, Koutsokera, Angela, Mazza Stalder, Jesica, Mitropoulou, Georgia, Panchaud, Alice   +6 more
core   +3 more sources

Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis

Medicina, 2022
Triple-combination therapy with elexacaftor, tezacaftor and ivacaftor has been recently approved for cystic fibrosis patients with at least one F508del mutation in the transmembrane conductance regulator of the cystic fibrosis gene.
Federica Li Pomi, Luca Di Bartolomeo, Mario Vaccaro, Maria Lentini, Simona Cristadoro, Maria Cristina Lucanto, Mariangela Lombardo, Stefano Costa, Francesco Borgia   +8 more
doaj   +1 more source

Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease

European Respiratory Review, 2020
Drug compounds that augment the production and activity of the cystic fibrosis (CF) transmembrane regulator (CFTR) have revolutionised CF care. Many adults and some children with CF suffer advanced and severe lung disease or await lung transplantation ...
Michal Shteinberg, Jennifer L. Taylor-Cousar   +1 more
doaj   +1 more source

Aplasia Cutis Congenita in the Setting of Maternal Cystic Fibrosis

Annals of Internal Medicine: Clinical Cases, 2022
Aplasia cutis congenita is a rare scalp defect. An affected neonate was delivered after in utero exposure beginning in the midtrimester to elexacaftor/tezacaftor/ivacaftor for maternal cystic fibrosis management. Although aplasia cutis congenita has many
Govind Kallumkal, Robert Egerman
doaj   +1 more source